| Literature DB >> 30004038 |
P Ungprasert1, K Wijarnpreecha2, C Thongprayoon2, W Cheungpasitporn3.
Abstract
Background: Previous studies have suggested an increased risk of hip fracture among patients with peripheral arterial disease (PAD), however, the results have been inconsistent. This meta-analysis was conducted with the aim to summarize all available evidence to better characterize the risk of incident hip fracture among these patients. Materials andEntities:
Keywords: Hip fracture; meta-analysis; osteoporosis; peripheral arterial disease
Mesh:
Year: 2018 PMID: 30004038 PMCID: PMC6198699 DOI: 10.4103/jpgm.JPGM_685_17
Source DB: PubMed Journal: J Postgrad Med ISSN: 0022-3859 Impact factor: 1.476
Figure 1Literature review and selection
Characteristics of the included studies
| Sennerby | Collins | Hyde | Reyes | Palaez | Liu | |
|---|---|---|---|---|---|---|
| Country of origin | Sweden | United States | Australia | Spain | Spain | Taiwan |
| Study design | Retrospective cohort | Prospective cohort | Prospective cohort | Retrospective cohort | Prospective cohort | Retrospective cohort |
| Year of publication | 2009 | 2009 | 2012 | 2014 | 2015 | 2017 |
| Cases | All patients in the Swedish twin Registry who were diagnosed with PAD. This registry included 15,968 pairs of twins born in Sweden between 1914 and 1944. | All subjects in the MrOS study who were diagnosed with PAD. This study recruited patients from 6 major metropolitan areas across the United States from March 2000 to April 2002. All patients underwent ABI testing to look for evidence of PAD. | All patients in the screening for vascular health study of the University of Western Australia who were diagnosed with PAD. This study recruited patients from April 1996 to June 1998. All patients underwent ABI testing to look for evidence of PAD. | All patients who were diagnosed with PAD before January 1, 2007. Cases were identified from the electronic database of the general practitioner of Catalonia, Spain which comprised over 2 million people. | Cases with PAD were recruited from residences of a nursing home in Valladolid, Spain. All residents underwent ABI testing to look for evidence of PAD. | All patients who were first diagnosed with PAD between January 1, 2000 and December 31, 2004. Cases were identified from the electronic database of the Taiwan’s National Health Insurance Program. |
| Diagnosis of PAD | Presence of diagnostic codes for PAD in the database plus telephone interview for confirmation. | ABI of <0.9. | ABI of <0.9. | Presence of diagnostic codes for PAD in the database. | ABI of<0.9. | Presence of diagnostic codes for PAD in the database. |
| Controls | The remaining patients without PAD and other cardiovascular diseases in the database served as controls. | The remaining patients without PAD in the cohort served as controls. | The remaining patients without PAD in the cohort served as controls. | The remaining patients without PAD in the database served as controls. | The remaining residences without PAD served as controls. | Sex and age-matched individuals without PAD who were randomly selected from the same database served as controls |
| Diagnosis of hip fracture | Presence of diagnostic codes for hip fracture in the database plus telephone interview for confirmation. | Periodic review of the medical records plus mail/telephone interview. | Periodic review of the medical records. | Presence of diagnostic codes for hip fracture in the database. | Periodic review of the medical records of the nursing home. | Presence of diagnostic codes for hip fracture in the database. |
| Follow-up | Until occurrence of study endpoint, death or December 31, 2005. | Until occurrence of study endpoint, death or August 1, 2007. | Until December 31, 2008. | Until December 31, 2009. | 20 months after the survey date. | Until occurrence of the study endpoint, death, emigration out of system, or December 31, 2008. |
| Number of cases | 1,061 | 358 | 506 | 7,305 | 18 | 6,647 |
| Number of controls | 19,089 | 5,423 | 3,815 | 178,866 | 54 | 26,588 |
| Mean age for cases/controls (years) | 69.0/62.0 | 77.0/73.3 | N.A. | N.A. | 88.0/82.5 | N.A. |
| Average duration of follow-up for cases/controls (years) | N.A. | 5.6 (overall) | 11.1 (overall) | 2.6/2.8 | 1.7/1.7 | 9.9/10.6 |
| Confounder adjusted for | Sex and comorbidities | Age, ethnicity, and study site | Age, BMI, smoking, alcohol use, and vascular comorbidities | Age, BMI, smoking, alcohol use, and comorbidities | None | Age, sex, comorbidities, medication, and socioeconomic status |
| Quality assessment (Newcastle-Ottawa scale) | Selection: 4 stars Comparability: 2 stars Outcome: 3 stars | Selection: 4 stars Comparability: 2 stars Outcome: 3 stars | Selection: 3 stars Comparability: 2 stars Outcome: 3 stars | Selection: 4 stars Comparability: 1 star Outcome: 3 stars | Selection: 3 stars Comparability: 1 star Outcome: 2 stars | Selection: 4 stars Comparability: 2 stars Outcome: 3 stars |
ABI: Ankle-brachial index, BMI: Body mass index, N.A: Not available, PAD: Peripheral arterial disease
Figure 2Forest plot of this meta-analysis
Figure 3Funnel plot of this meta-analysis